Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
2024

Tofacitinib for Psoriatic Arthritis After Adalimumab

Sample size: 180 publication Evidence: moderate

Author Information

Author(s): Gladman Dafna D., Nash Peter, Mease Philip J., FitzGerald Oliver, Duench Stephanie, Cadatal Mary Jane, Masri Karim R.

Primary Institution: University of Toronto

Hypothesis

Can patients with psoriatic arthritis safely switch from adalimumab to tofacitinib without a washout period?

Conclusion

Tofacitinib efficacy and safety were similar in patients who switched from adalimumab to tofacitinib and those who continued tofacitinib, indicating a direct switch is feasible.

Supporting Evidence

  • 180 patients were included in the analysis.
  • Patients who switched maintained similar efficacy outcomes.
  • Safety profiles were comparable between the two treatment groups.
  • Most patients who responded to adalimumab also responded to tofacitinib after switching.

Takeaway

This study shows that people with psoriatic arthritis can switch from one medicine to another without waiting, and it still works well.

Methodology

Patients received either tofacitinib or adalimumab in a Phase 3 study and then switched to tofacitinib in a long-term extension study.

Potential Biases

Selection bias may have occurred as only patients who completed the Phase 3 study were included.

Limitations

The analysis was post hoc, the sample size was small, and the timeframe was short.

Participant Demographics

{"age":{"median":48,"range":"23-72"},"gender_distribution":{"female_percentage":50.6},"ethnicity":{"white_percentage":97.8}}

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13075-024-03442-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication